Clarity Pharmaceuticals Ltd (CU6)
CXA 
Summary
Clarity Pharmaceuticals Ltd (CU6) FAQ
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Clarity Pharmaceuticals Ltd ever had a stock split?
Clarity Pharmaceuticals Ltd Profile
| Biotechnology Industry | Healthcare Sector | Ms. Michelle Parker CEO | CXA Exchange | AU0000165375 ISIN |
| Australia Country | 50 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Clarity Pharmaceuticals Ltd is a forward-thinking clinical stage radiopharmaceutical company that concentrates on innovating theranostic (therapeutic and diagnostic) therapy and imaging products aimed at combating cancer in both children and adults. Established in 2010, the company has positioned itself as a trailblazer in the field of radiopharmaceuticals, leveraging cutting-edge technology to develop treatments that offer both diagnostic and therapeutic solutions. Based in Sydney, Australia, Clarity Pharmaceuticals is dedicated to advancing its unique approach to cancer treatment, aiming to improve outcomes and quality of life for patients worldwide.
Products and Services
Clarity Pharmaceuticals Ltd has developed a robust pipeline of products designed to address the critical need for effective cancer diagnosis and treatment through targeted theranostic radiopharmaceuticals. The company's product lineup includes:
- SARTATE™: Serving as the lead product, SARTATE is a novel targeted theranostic radiopharmaceutical that is revolutionizing the way cancers expressing somatostatin receptor 2 are diagnosed, staged, and treated. Its innovative approach allows for more accurate cancer detection and the delivery of targeted therapy, thereby enhancing treatment efficacy and patient outcomes.
- SAR-Bombesin: This pan-cancer theranostic radiopharmaceutical is designed for the diagnosis, staging, and treatment of cancers that express gastrin-releasing peptide receptor. SAR-Bombesin represents Clarity Pharmaceuticals' commitment to expanding the scope of cancers that can be effectively targeted and treated with its theranostic solutions, offering hope to a broader range of patients.
- SAR-bisPSMA: Targeted specifically at cancers that express the prostate-specific membrane antigen (PSMA), SAR-bisPSMA is a theranostic radiopharmaceutical under development. It underscores Clarity Pharmaceuticals' dedication to leveraging theranostics for the precise diagnosis, staging, and treatment of cancer, with a particular focus on advancing prostate cancer care.
